Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Ahead Of The Fed
Aug 04, 2008 10:48 AM
- Analyst Comments: EOG Resources, Charlotte Russe, VeraSun Energy, Thornburg Mortgage, Amicus Therapeutics
Jul 31, 2008 04:00 PM
- Weak Economic Data
Jul 31, 2008 10:52 AM
- Big Earnings Week
Jul 21, 2008 10:17 AM
- Shire Pharma Looks Past Adderall
Jun 26, 2008 05:01 PM
- Play The Oversold Bounce
Jun 12, 2008 10:30 AM
- Confidence In The Fed
Jun 10, 2008 12:15 PM
- Market Report for Tuesday
May 20, 2008 12:10 PM
- Analyst Comments: Trident, Liberty Property, Shire Pharmaceuticals, Stericycle
Apr 29, 2008 07:19 PM
- Pre-Market
Apr 20, 2008 02:29 PM
- Shire Plc: Investor Seminar
Nov 18, 2008 09:04 AM
- Confirmation of HGT Business Day - 18th November 2008
Nov 12, 2008 11:53 AM
- Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
Nov 05, 2008 02:31 PM
- Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
Oct 29, 2008 12:01 PM
- Shire's New Product Portfolio Delivers Strong Quarterly Performance
Oct 29, 2008 09:35 AM
- Beacon Equity Issues Technical Trade Alerts on Recent Analyst Upgrades: LPX, SHPGY, WNR, WIN, AMLN, STEC
Oct 08, 2008 10:20 AM
- Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
Oct 07, 2008 09:01 AM
- Shire Announces Results from a Multidisciplinary Analysis of the Drug Release Profiles of LIALDA(R) (mesalamine) and Asacol(R) (mesalamine) for the Treatment of Ulcerative Colitis (UC) at the American College of Gastroenterology (ACG) Meeting
Oct 06, 2008 08:02 AM
- Change of Name to Shire plc
Oct 01, 2008 05:19 AM
- Results of the Annual General Meeting Held on September 24, 2008
Sep 24, 2008 09:51 AM
Analyst Ratings
|
|
Share Performance
|
Period
|
SHPGY
|
Compare to S&P
|
| YTD |
-40.54 %
|
-2.58 %
|
| 4 Weeks |
3.93 %
|
12.34 %
|
| 12 Weeks |
-19.20 %
|
12.01 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 23.16 %
|
|
EPS Growth in Last Year: 77.27 %
|
|
Sales Growth in Last Quarter: 0.39 %
|
|
Sales Growth in Last Quarter: 27.91 %
|
|
|
